Outcomes of Kidney Allograft and Recipient Survival After Liver Transplantation by Induction Type in the United States

Samy M. Riad, Nicholas Lim, Scott Jackson, Arthur J. Matas, John Lake – 18 June 2021 – There are several choices for induction immunosuppression in kidney‐after‐liver transplantation. We used the Scientific Registry of Transplant Recipients database. We assessed all kidney‐after‐liver transplant recipients in the United States between 1/1/2000 and 7/31/2017 to study kidney graft and patient outcomes by induction type. We only included patients discharged on tacrolimus and mycophenolate with or without steroids and had a negative crossmatch before kidney engraftment.

Estimating Glomerular Filtration Rate in Cirrhosis Using Creatinine‐Based and Cystatin C–Based Equations: Systematic Review and Meta‐Analysis

Prianka Singapura, Tsung‐Wei Ma, Naveed Sarmast, Stevan A. Gonzalez, François Durand, Rakhi Maiwall, Mitra K. Nadim, John Fullinwider, Giovanna Saracino, Claire Francoz, Rebecca Sartin, James F. Trotter, Sumeet K. Asrani – 17 June 2021 – Accurate estimation of kidney function in cirrhosis is crucial for prognosis and decisions regarding dual‐organ transplantation. We performed a systematic review/meta‐analysis to assess the performance of creatinine‐based and cystatin C (CysC)–based eGFR equations compared with measured GFR (mGFR) in patients with cirrhosis.

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

Florian Bömmel, Thomas Berg – 17 June 2021 – Systematic discontinuation of long‐term treatment with nucleos(t)ide analogues (NAs) is one strategy to increase functional cure rates in patients with chronic hepatitis B e antigen (HBeAg)–negative hepatitis B. Currently, available study results are heterogeneous; however, long‐term hepatitis B surface antigen (HBsAg) loss rates of up to 20% have been reported in prospective trials. This review proposes criteria that can be used when considering NA discontinuation in patients with chronic hepatitis B virus (HBV).

Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort

Jun Wang, David V. Conti, David Bogumil, Xin Sheng, Mazen Noureddin, Lynne R. Wilkens, Loic Le Marchand, Hugo R. Rosen, Christopher A. Haiman, Veronica Wendy Setiawan – 17 June 2021 – Most genetic studies of nonalcoholic fatty liver disease (NAFLD) have been conducted in Whites. In this large and ethnically diverse cohort, we assessed the transportability of previously identified genetic variants for NAFLD, built a genetic risk score (GRS), and examined its association with NAFLD risk in multiple ethnic groups.

Hepatology Highlights

Muzammil Muhammad Khan, Maria Alejandra Luna‐Cuadros, Daryl T.Y. Lau, Tejasav S. Sehrawat, Ojasav Sehrawat, Robert E. Schwartz, Anthony J. Choi, Robert S. Brown, Gopanandan Parthasarathy, Enis Kostallari, Nidhi Jalan‐Sakrikar, David M. Salerno, Chaitanya Allamneni, Ravi S. Vora, Jessica L. Maiers – 17 June 2021

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD

Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, Michihiro Nonaka, Hideyuki Hyogo, Hideki Fujii, Tomoaki Nakajima, Kento Imajo, Kenichi Tanaka, Yoshihito Kubotsu, Hiroshi Isoda, Satoshi Oeda, Osamu Kurai, Masato Yoneda, Masafumi Ono, Yoichiro Kitajima, Ryo Tajiri, Ayako Takamori, Atsushi Kawaguchi, Shinichi Aishima, Masayoshi Kage, Atsushi Nakajima, Yuichiro Eguchi, Keizo Anzai – 16 June 2021 – Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined.

Subscribe to